PDF(713 KB)
PDF(713 KB)
PDF(713 KB)
螺内酯治疗难治性高血压的研究进展
Research progress of treatment against resistant hypertension by spironolactone
难治性高血压一直是高血压治疗的难点，通常使用多种药物治疗仍不能达标，能引起心、脑、肾等严重靶器官损害。近年来研究发现，在原治疗基础上加用螺内酯能有效促进难治性高血压的达标，故本文就螺内酯的作用机制和临床应用进行综述。
Resistant hypertension is difficult to be cured, though many drugs have been developed. Moreover, antihypertensive drugs can cause many adverse drug reactions and damage organs such as heart, brain, kidney, etc.. In recent years, it is found that spironolactone added into basic therapeutic regimen can effectively improve therapeutic effects of resistant hypertension. Therefore, this paper summarizes mechanism and rational use of spironolactone in literatures.
螺内酯 / 难治性高血压 {{custom_keyword}} /
spironolactone / resistant hypertension {{custom_keyword}} /
[1] Henine N, Kichou B, Kichou L, et al. Prevalence of true resistant hypertension among uncontrolled hypertensive patients referred to a tertiary health care center[J]. Ann Cardiol Angeiol (Paris), 2016, 65(3): 191-196.
[2] Muiesan ML, Salvetti M, Rizzoni D, et al. Resistant hypertension and target organ damage[J]. Hypertens Res, 2013, 36(6): 485-491.
[3] Edwards E, Dipette DJ. Editorial commentary:resistant hypertension:pathogenesis and current and future management[J]. Trends Cardiovas Med, 2016,26(8): 30066-30067.
[4] Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J]. Hypertension, 2008, 51(6): 1403-1419.
[5] 梁碧波,王玉涛.醛固酮受体拮抗剂螺内酯在临床中的应用及研究进展[J].中国医院药学杂志,2010,30(19):1688-1689.
[6] 梁晓坤.醛固酮受体拮抗剂临床应用研究进展[J].中国伤残医学,2012,20(7):138-139.
[7] 曲高婷,张爱青,施会敏,等.自噬对体外醛固酮诱导的大鼠系膜细胞凋亡的影响[J].皖南医学院学报,2016,35(2):113-116, 117.
[8] 刘振东,路方红.醛固酮、醛固酮合成酶CYP11B2基因-344C/T多态性与原发性高血压关系的研究进展[J].现代中西医结合杂志,2006,15(22):3166-3168.
[9] 郭建淑,陈明,吴可贵.高血压患者血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂治疗后醛固酮逃逸的对比研究[J].中华高血压杂志,2015(3):300.
[10] Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase[J]. J Hypertens, 1994, 12(9): S17-S22.
[11] Navaneethan SD, Bravo EL. Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?[J]. Clin J Am Soc Nephrol, 2013, 8(10): 1637-1639.
[12] 郭建淑.醛固酮逃逸的研究进展[J].心血管病学进展,2011,32(4):562-565.
[13] Navaneethan SD, Bravo EL. Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?[J]. Clin J Am Soc Nephrol, 2013, 8(10): 1637-1639.
[14] 余国膺.人的胃促胰酶-血管紧张素系统[J].高血压杂志,1994(2):100-103.
[15] Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype[J]. J Am Coll Cardiol, 2001, 37(7): 1808-1812.
[16] 周展,陈慧,吴小盈.醛固酮与原发性高血压患者胰岛素抵抗的相关性[J].中华高血压杂志,2009(7):652-653.
[17] Huan Y, Deloach S, Keith SW, et al. Aldosterone and aldosterone: renin ratio associations with insulin resistance and blood pressure in African Americans[J]. J Am Soc Hypertens, 2012, 6(1): 56-65.
[18] 田刚,郑丽君,卢群.小剂量螺内酯联合氨氯地平对肥胖高血压患者血压和胰岛素抵抗的影响[J].临床荟萃,2010,25(1):12-14.
[19] Kumagai E, Adachi H, Jacobs DR, et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population[J]. Hypertension, 2011, 58(6): 1043-1048.
[20] Luther JM, Luo P, Kreger MT, et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets[J]. Diabetologia, 2011, 54(8): 2152-2163.
[21] Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines[J]. Circulation, 2008, 117(17): 2253-2261.
[22] 解柳芸.老年高血压与胰岛素抵抗的相关性研究[J].中外医学研究,2016,14(2):44-45.
[23] Ogino K, Kinugasa Y, Kato M, et al. Spironolactone,not furosemide,improved insulin resistance in patients with chronic heart failure[J]. Int J Cardiol, 2014, 171(3): 398-403.
[24] Ronconi V, Turchi F, Appolloni G, et al. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists[J]. Curr Vasc Pharmacol, 2012, 10(2): 238-246.
[25] 陈冰雪,刘莉,王凤飞,等.螺内酯对高血压病患者血管内皮细胞功能的影响[J].白求恩军医学院学报,2005,3(2):72-74.
[26] 朱秀兰.螺内酯对高血压患者心室及血管重构的影响[J].西部医学,2012,24(7):1334-1336.
[27] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93.
[28] Widimsky J. PATHWAY-2 study:spironolactone vs placebo,bisoprolol and doxazosin to determine optimal treatment of resistant hypertension.spironolactone high effective in lowering blood pressure in drug resistant hypertension[J]. Vnitr Lek, 2015, 61(12): 1067-1071.
[29] Guo HY, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials[J]. Int J Clin Exp Med, 2015, 8(5): 7270-7278.
[30] 毛瑞芬.常规治疗加用螺内酯片治疗难治性高血压的临床效果观察[J].当代医学,2014(17):136-136.
[31] 陆东升.螺内酯在顽固性高血压联合治疗中的疗效观察[J].浙江医学,2014(6):526-527.
[32] Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) A randomized, Double-Blind, Placebo-Controlled trial[J]. Hypertension, 2011, 57(6): 1U94-1069.
[33] 盖延红,栾晓东,朱为勇,等.螺内酯治疗不同年龄难治性高血压的疗效差别[J].中国循证心血管医学杂志,2015(4):537-538, 541.
[34] 刘成.ACEI联合小剂量螺内酯治疗肾性难治性高血压的疗效观察[J].中国医疗前沿,2012,7(14):15-15, 27.
[35] Hirsch JS, Drexler Y, Bomback AS. Aldosterone blockade in chronic kidney disease[J]. Semin Nephrol, 2014, 34(3): 307-322.
[36] Barrera-Chimal J, Perez-Villalva R, Rodriguez-Romo R, et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury[J]. Kidney Int, 2013, 83(1): 93-103.
[37] Garg R, Rao AD, Baimas-George M, et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes[J]. Diabetes, 2015, 64(1): 236-242.
[38] Song PS, Kim DK, Kim KH, et al. Spironolactone lowers the rate of repeat revascularization in acute myocardial infarction patients treated with percutaneous coronary intervention[J]. Eur Heart J, 2014, 35(1): 1155.
[39] Wu CT, Wang ZH, Zq L, et al. Effect of spironolactone on cardiac remodeling after acute myocardial infarction[J]. World J Emerg Med, 2013, 4(1): 48-53.
[40] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). developed with the special contribution of the heart failure association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8): 891-975.
[41] Oyamada N, Sone M, Miyashita K, et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia[J]. Endocrinology, 2008, 149(8): 3764-3777.
[42] 魏守蓉,陈敏,张军辉,等.螺内酯对减少缺血性脑卒中患者MES的作用研究[J].河北医药,2016(1):68-70.
[43] Kim YN, Park K, Gwoo S, et al. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease[J]. Nephrol Dialy Transplantation, 2014, 29(3): 160.
[44] Ni XY, Zhang JS, Zhang P, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study[J]. J Clin Hypertens, 2014, 16(9): 658-663.
[45] 杨省利,潘军强,张殿新,等.小剂量螺内酯治疗顽固性高血压病的疗效和安全性[J].心脏杂志,2011(6):822-823.
[46] 杨萌,朱明明,郭康,等.166例难治性高血压患者的临床治疗与效果研究[J].中国卫生产业,2014,11(6):2-4.
/
| 〈 |
|
〉 |
